Marvel Biosciences Corp (MRVL) - Total Liabilities
Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has total liabilities worth CA$4.33 Million CAD (≈ $3.14 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Marvel Biosciences Corp (MRVL) equity growth momentum to track the company's year-over-year net asset growth rate.
Marvel Biosciences Corp - Total Liabilities Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp's total liabilities have evolved over time, based on quarterly financial data.
Marvel Biosciences Corp Competitors by Total Liabilities
The table below lists competitors of Marvel Biosciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digistar Corporation Bhd
KLSE:0029
|
Malaysia | RM225.61 Million |
|
HLT Global Bhd
KLSE:0188
|
Malaysia | RM76.94 Million |
|
Ecoslops SA
PA:ALESA
|
France | €19.77 Million |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
Germany | €8.43 Million |
|
Rossi Residencial S.A
SA:RSID3
|
Brazil | R$1.21 Billion |
|
Altheora SA
PA:ALORA
|
France | €23.25 Million |
|
Pantera Lithium Ltd
AU:PFE
|
Australia | AU$8.20 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Marvel Biosciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Marvel Biosciences Corp market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marvel Biosciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marvel Biosciences Corp (2020–2025)
The table below shows the annual total liabilities of Marvel Biosciences Corp from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$4.33 Million ≈ $3.13 Million |
+30.62% |
| 2024-07-31 | CA$3.32 Million ≈ $2.40 Million |
+38.65% |
| 2023-07-31 | CA$2.39 Million ≈ $1.73 Million |
+233.21% |
| 2022-07-31 | CA$718.00K ≈ $519.39K |
+538.36% |
| 2021-07-31 | CA$112.48K ≈ $81.36K |
-36.52% |
| 2020-07-31 | CA$177.18K ≈ $128.17K |
-- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more